Helsinn Group and Pharmacosmos have entered an agreement for the exclusive U.S. commercialization rights to Monofer, an intravenous iron replacement therapy under development for the treatment of iron deficiency anemia. Helsinn has exclusive rights to commercialize Monofer and any other iron isomaltoside 1000 products developed by Pharmacosmos in the U.S.   Pharmacosmos is eligible for milestone payments of as much as $130 million for Monofer and will be eligible to receive further payments for ...